5326602025-10-012025-12-315326602025-04-012025-12-315326602025-10-012025-12-31in-capmkt:OtherExpenses1Member5326602025-04-012025-12-31in-capmkt:OtherExpenses1Member5326602025-10-012025-12-31AuditorDomain15326602025-10-012025-12-31in-capmkt:AuditedMember5326602025-12-31in-capmkt:AuditedMember5326602025-10-012025-12-31in-capmkt:AdjustedMember5326602025-12-31in-capmkt:AdjustedMember5326602025-10-012025-12-31AuditQualification15326602025-10-012025-12-31AuditQualification25326602025-10-012025-12-31AuditQualification3iso4217:INRiso4217:INRxbrli:shares532660VIVIMEDLABNAINE526G01021VIVIMED LABS LIMITEDMain BoardEquity2025-04-012026-03-312026-03-13INRMillionsQuarterlyThird quarterSingle segmentPharma2026-03-1316:00:002026-03-1321:30:00Statement on impact of audit qualification2025-10-012025-12-31UnauditedConsolidated1598900000159890000892600000-10280000369500001004000046280000153180000325430000-1655400000-1655400000000-1655400000000-1655400000-16554000000-0.88-0.8500-0.88-0.852025-04-012025-12-31UnauditedConsolidated579890000572000058561000025001000001813000014996000032230000145450000283320000879100000-2934900000-2934900000000-2934900000000-2934900000-29349000000-3.54-3.4400-3.54-3.44other153180000other283320000UnauditedQualified opinionSVRL and cotrue2027-04-305856100005856100008791000001351470000-293490000-765860000-3.54-9.230000-645170000-1245490000Based on information provided to us by the management, Vivimed Labs Limited has not provided for interest, penal interest and penal charges approximately amounting to 164.52 million on an accrual basis for the Quarter ended 31.12.2025, (472.37 million for the year to date 31.12.2025) pertaining to loans. [Term Loans and Working capital Loans]. Meanwhile, we are in the process of obtaining direct balance confirmation from the banks. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards.Qualified opinionRepetitiveThe Company is engaged in the negotiations with its Bankers for a settlement and is confident for settlement with Banks. Hence, the company has not recorded interest on outstanding loan for the year 2025-26.NONONOAn extract of forensic audit report relating to certain transactions of earlier financial years, conducted during the FY 2022-23 is received by us during the current period. We are presently in the process of evaluating the observations and assessing the possible financial impact, if any. Pending completion of such evaluation, no adjustments have been made in the current financial results.Qualified opinionWhether appeared first timeWe have provided explanations and also are in the process of providing related documents and additional information for the verification of auditors.NONONOThe Company has recognized a provision for commission expenses amounting to 46.03 million relating to sales of earlier financial years based on proforma invoices. As at the reporting date, the Company is in the process of obtaining supporting documents, confirmations and other relevant documentation to substantiate the existence and measurement of the obligation.Qualified opinionWhether appeared first timeThe company has made provision based on the agreements with Dealers and are in the process of obtaining invoices with relevant supporting evidences. NONONOSantosh VaralwarNoJarugula Siva PrasadG Ramakrishna-Hyderabad2026-03-13